| Q82209172 | A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib |
| Q90777008 | Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia |
| Q38707841 | Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia |
| Q64078547 | Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs |
| Q38025714 | Antineoplastic drug-induced bradyarrhythmias. |
| Q38313870 | Cancer chemotherapy and cardiac arrhythmias: a review. |
| Q33574045 | Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention |
| Q93541691 | Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy |
| Q51191703 | Cardiovascular differentiation of imatinib and bosutinib in the rat. |
| Q41348012 | Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance |
| Q37967508 | Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology |
| Q36006389 | Clinical cardiac safety profile of nilotinib |
| Q88495607 | Cost-Effectiveness of Routine Screening for Cardiac Toxicity in Patients Treated with Imatinib in Brazil |
| Q48492330 | Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia |
| Q26749324 | European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia |
| Q39253982 | High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model |
| Q34620781 | Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas. |
| Q38076114 | Imatinib-induced decompensated heart failure in an elderly patient with chronic myeloid leukemia: case report and literature review |
| Q85228971 | Is imatinib-related cardiotoxicity still an open issue? |
| Q33849146 | Practical management of patients with chronic myeloid leukemia |
| Q34443523 | Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase |
| Q35008126 | Review of cardiotoxicity in pediatric cancer patients: during and after therapy |
| Q36306823 | Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome |
| Q37814085 | Targeting non-malignant disorders with tyrosine kinase inhibitors. |
| Q58847619 | The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients |
| Q36999931 | Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice |
| Q27027354 | Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity |
| Q84597676 | [New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part A: heart] |